thermo fisher scientific inc (TMO) Snapshot

Perfinity Biosciences Inc. announced the signing of an agreement with Thermo Fisher Scientific Inc. to co-market an automated protein sample preparation and analysis system. This solution combines Perfinity's automated sample preparation platform with Thermo Fisher Scientific's liquid chromatography and mass spectrometry instrumentation. There are applications in biopharmaceutical process monitoring, protein drug development and biomarker discovery. Perfinity's sample preparation platform is an automated system that reduces the time required for the trypsin digestion step prior to mass spec analysis from approximately 18 hours using conventional techniques to less than two minutes. The proprietary three-column system is based on the company's trypsin columns, and also includes an automated workstation and software. Thermo Fisher is providing Thermo Scientific UltiMate 3000 UHPLC systems and a choice of Orbitrap-based hybrid or triple quadrupole mass spectrometers depending on customers' specific requirements.

Thermo Fisher Scientific, Inc. launched three new-generation liquid chromatography-mass spectrometry (LC-MS) instruments that redefine high-performance analysis and enable customers in research and applied markets to push the boundaries of science. Thermo Scientific Orbitrap Fusion LC-MS with Thermo Scientific Dionex UltiMate 3000 Series UHPLC. The new Thermo Scientific platforms made their debut at the ASMS Conference on Mass Spectrometry and Allied Topics, being held in Minneapolis from June 9-13 at the Minneapolis Convention Center in booth 154. The innovations making headlines at this year's ASMS 2013 include: Thermo Scientific Orbitrap Fusion "Tribrid" mass spectrometer, a new top-of-the-line research instrument that uniquely combines three Thermo Fisher mass analyzers -- the industry-leading Orbitrap, quadrupole and linear ion trap -- for unprecedented analytical capabilities in proteomics, lipidomics, glycoproteomics and other life sciences research. Thermo Scientific Quantiva triple-stage quadrupole mass spectrometer, a triple quadrupole mass spectrometer that was built from the ground up to deliver ultimate sensitivity, speed and dynamic range for challenging quantitation experiments, such as detecting ultra-low levels of peptides for cancer research. Thermo Scientific Endura triple-stage quadrupole mass spectrometer, a completely new instrument that offers exceptional quantitative value and sensitivity coupled with robustness and ease-of-use for scientists who run high-volume applied analyses, such as food and environmental testing. Thermo Fisher's new generation of mass spectrometers for qualitative and quantitative research redefine high performance by combining revolutionary depth of analysis with ease-of-use. These instruments were specifically developed to address growing customer needs to run more samples in less time, achieve ever-lower detection limits and analyze increasingly complex biological samples, such as protein-based biopharmaceuticals. The Orbitrap Fusion mass spectrometer features novel "Tribrid" architecture with three mass analyzers, offering greater depth of analysis of complex biological samples to provide new levels of knowledge. It offers up to 450,000 resolution, which allows life sciences researchers, for example, to measure extremely low-concentration drug metabolites that could not previously be identified. In addition, the Orbitrap Fusion can enable scientists to conduct a wide range of existing experiments faster and more effectively to accelerate the discovery process. Scientists performing quantitation experiments -- from proteomics and toxicology to food and environmental testing -- now have a powerful new tool in the TSQ Quantiva triple quadrupole instrument. It delivers robust analytical performance with attogram (10(-18) gram) sensitivity for customers who require the absolute lowest levels of detection. Thermo Fisher also developed a new suite of software designed to make the power of these new- generation mass spectrometers accessible to a wider customer set by improving usability and increasing the speed of analysis. For the Orbitrap Fusion, new software powered by Dynamic Scan Management tools automatically adjusts scan parameters in real time to achieve faster results. It eliminates guesswork so scientists can conserve precious samples during analysis. New Method Editor software for the TSQ Quantiva is designed to allow customers to rapidly develop new methods, improving reporting and productivity. Further strengthening its depth of capabilities, Thermo Fisher introduced several other new reagents: Thermo Scientific Pierce Trypsin Protease, MS Grade for protein digestion. Thermo Scientific Pierce Mass Spec Sample Prep Kit for Cultured Cells, an easy-to-use comprehensive kit for preparing clean peptide mixtures. Thermo Scientific Pierce Abundant Protein Depletion Products, spin columns for removing albumen and antibody components from human plasma for mass spec or electrophoresis analysis. Thermo Scientific Pierce Reserpine Standard for LC-MS.

On May 31, 2013, Thermo Fisher Scientific, Inc. entered into a bridge credit agreement and a term loan agreement. The bridge credit agreement is a 364-day unsecured committed bridge facility in the principal amount of $7.5 billion, among the company and a certain foreign subsidiary of the company from time to time party thereto, as borrowers, JPMorgan Chase Bank, N.A., as administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (initially consisting of JPMorgan Chase Bank, N.A., Barclays Bank PLC, Bank of America, N.A., The Bank of Tokyo-Mitsubishi UFJ Ltd., The Royal Bank of Scotland plc, BNP Paribas, Credit Suisse AG, Cayman Islands Branch, Goldman Sachs Bank USA, HSBC Bank USA, N.A., Morgan Stanley Senior Funding, Inc., Citibank, N.A., Mizuho Corporate Bank Ltd., Sumitomo Mitsui Banking Corporation, U.S. Bank, National Association, Bank of China, New York Branch, The Bank of New York Mellon, The Bank of Nova Scotia, ING Bank N.V., Dublin Branch, Intesa Sanpaolo Spa, KBCM Bridge LLC and Nordea Bank Finland Plc) as lenders, Barclays Bank PLC, as syndication agent, and J.P. Morgan Securities LLC and Barclays Bank PLC, as joint lead arrangers and joint bookrunners. The closing date of the bridge credit agreement is conditioned on, among other things, the consummation of the acquisition of Life Technologies Corporation, pursuant to that certain Agreement and Plan of Merger, dated as of April 14, 2013, among the company, Polpis Merger Sub Co. and Life Technologies. The term loan agreement is a 3-year unsecured term loan facility in the principal amount of $5.0 billion, among the company and a certain foreign subsidiary of the company from time to time party thereto, as borrowers, JPMorgan Chase Bank, N.A., as administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (initially consisting of JPMorgan Chase Bank, N.A., Barclays Bank PLC, Bank of America, N.A., The Bank of Tokyo-Mitsubishi UFJ Ltd., The Royal Bank of Scotland plc, BNP Paribas, Credit Suisse AG, Cayman Islands Branch, Goldman Sachs Bank USA, HSBC Bank USA, N.A., Morgan Stanley Bank, N.A., Citibank, N.A., Mizuho Corporate Bank Ltd., Sumitomo Mitsui Banking Corporation, U.S. Bank, National Association, Bank of China, New York Branch, The Bank of New York Mellon, The Bank of Nova Scotia, ING Bank N.V., Dublin Branch, Intesa Sanpaolo Spa, Nordea Bank Finland Plc, The Royal Bank of Scotland Finance Ireland, Bank of the West, Key Bank National Association and First Hawaiian Bank) as lenders, Barclays Bank PLC and Bank of America, N.A., as co-syndication agents, J.P. Morgan Securities LLC, Barclays Bank PLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated as joint lead arrangers, J.P. Morgan Securities LLC, Barclays Bank PLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, The Bank of Tokyo-Mitsubishi UFJ Ltd., RBS Securities Inc., BNP Paribas Securities Corp., Credit Suisse AG, Cayman Islands Branch, Goldman Sachs Bank USA, HSBC Bank USA, N.A. and Morgan Stanley Senior Funding, Inc. as joint bookrunners, The Bank of Tokyo-Mitsubishi UFJ Ltd., The Royal Bank of Scotland plc, BNP Paribas, Credit Suisse AG, Cayman Islands Branch, Goldman Sachs Bank USA, HSBC Bank USA, N.A. and Morgan Stanley Senior Funding, Inc. as co-documentation agents, and Citibank, N.A., Mizuho Corporate Bank Ltd., Sumitomo Mitsui Banking Corporation, U.S. Bank, National Association, Bank of China, New York Branch, The Bank of New York Mellon, The Bank of Nova Scotia, ING Bank N.V., Dublin Branch, Intesa Sanpaolo Spa, Key Bank National Association and Nordea Bank Finland Plc as co-agents. The closing date of the term loan agreement is conditioned on, among other things, the consummation of the Life Technologies acquisition.